Myovant Sciences Ltd (NASDAQ:MYOV) has received an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $20.00.

A number of brokerages have recently weighed in on MYOV. JMP Securities reiterated an “outperform” rating and set a $25.00 price target (up previously from $23.00) on shares of Myovant Sciences in a report on Wednesday, October 4th. Robert W. Baird reissued a “buy” rating and set a $20.00 price objective on shares of Myovant Sciences in a research report on Wednesday, October 4th. Cowen and Company reissued a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, October 3rd. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Finally, Evercore ISI initiated coverage on Myovant Sciences in a research report on Wednesday, August 16th. They set an “outperform” rating for the company.

ILLEGAL ACTIVITY NOTICE: “Myovant Sciences Ltd (MYOV) Receives Average Rating of “Buy” from Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/26/myovant-sciences-ltd-myov-receives-average-rating-of-buy-from-brokerages-2.html.

Myovant Sciences (NASDAQ:MYOV) traded down 1.58% during trading on Thursday, hitting $13.10. The stock had a trading volume of 7,577 shares. The firm’s market cap is $797.06 million. The firm’s 50 day moving average is $13.96 and its 200 day moving average is $13.96. Myovant Sciences has a 1-year low of $9.92 and a 1-year high of $18.85.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantitative Systematic Strategies LLC acquired a new stake in Myovant Sciences during the second quarter valued at $165,000. Goldman Sachs Group Inc. acquired a new stake in Myovant Sciences during the second quarter valued at $174,000. Wells Fargo & Company MN boosted its position in Myovant Sciences by 331.9% during the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after purchasing an additional 12,700 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Myovant Sciences by 36.3% during the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after purchasing an additional 6,330 shares during the last quarter. Finally, Swiss National Bank acquired a new stake in Myovant Sciences during the second quarter valued at $294,000.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.